Cholesterol Lowering and Residual Risk in Diabetes, Type 1
Cholesterol Lowering and Residual Risk in Diabetes, Type 1
Recruiting · NCT05641753 · Registry updated 2025-12-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Cholesterol Lowering and Residual Risk in Diabetes, Type 1 | Nutritional and Metabolic Diseases, autoimmune disease, diabetes mellitus, endocrine system disorder, glucose metabolism disease, immune system disorder, metabolic disease, type 1 diabetes mellitus | Recruiting | Phase 4 | 2025-12-29 | NCT05641753 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | 791 |
| NYU Langone Health | 359 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Mount Sinai School of Medicine | New York | United States | 15 |
| New York VA Hospital | New York | United States | 1 |
| NYC Health + Hospitals/Bellevue | New York | United States | 6 |
| NYU Langone Health | New York | United States | 403 |